newsfilter
← Latest News
GlobeNewswire·

Lyell Immunopharma Announces $80 Million Private Placement to Advance Ronde-Cel Toward Planned BLA Submission

Investors include ARCH Venture Partners, Adage Capital Management LP, Caligan Partners LP, RTW Investments, a leading mutual fund and other new and existing institutional investors.Ronde-cel, a next-generation CD19/CD20